Bristol-Myers Squibb Company
Antisense Oligonucleotides Targeting Alpha-Synuclein and Uses Thereof

Abstract:

The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.